Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 4/20 | 0.39 |
| ▸ | PRSS1 | P07477 | 4/20 | 0.39 |
| ▸ | PRSS2 | P07478 | 4/20 | 0.39 |
| ▸ | PRSS3 | P35030 | 4/20 | 0.39 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | CES2 | O00748 | 1/20 | 0.31 |
| ▸ | CES1 | P23141 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.30 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2007836 | 0.91 | F2 (0.40) | F2PRSS1PRSS2PRSS3AKR1C3 | |
| SCHEMBL2007971 | 0.88 | F2 (0.37) | F2PRSS1PRSS2PRSS3KMT2A | |
| SCHEMBL2009836 | 0.85 | F2 (0.40) | F2PRSS1PRSS2PRSS3KMT2A | |
| SCHEMBL2008662 | 0.84 | F2 (0.41) | F2PRSS1PRSS2PRSS3KMT2A | |
| SCHEMBL2006954 | 0.82 | KMT2A (0.41) | F2PRSS1PRSS2PRSS3KMT2A | |
| SCHEMBL2006952 | 0.82 | KMT2A (0.41) | F2PRSS1PRSS2PRSS3KMT2A | |
| SCHEMBL2014079 | 0.81 | CA2 (0.39) | KMT2ACES2CES1MAPTGAA | |
| SCHEMBL2007472 | 0.81 | CES2 (0.38) | KMT2ACES2CES1MAPTGAA | |
| SCHEMBL2008403 | 0.81 | KAT6A (0.37) | F2PRSS1PRSS2PRSS3AKR1C3 | |
| SCHEMBL2007676 | 0.81 | F2 (0.36) | F2PRSS1PRSS2PRSS3KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1864976-B1 | PROPANE-1,3-DION DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC (JP) | 2012-10-10 | — | — | EP | disclosed |
| US-7960562-B2 | Propane-1,3-dione derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2011-06-14 | — | — | US | disclosed |
| US-20090181964-A1 | Propane-1,3-Dione Derivative or Salt Thereof | ASTELLAS PHARMA INC. | 2009-07-16 | — | — | US | disclosed |
| EP-1864976-A1 | PROPANE-1,3-DION DERIVATIVE OR SALT THEREOF | Astellas Pharma Inc. (JP) | 2007-12-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090181964-A1 | Propane-1,3-Dione Derivative or Salt Thereof | GNRHR, KISS1R, FSHR | F2 1765/4885PRSS1 802/4885PRSS2 1576/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.